Gail Holmes Equine Orthopaedic Research Center, Colorado State University, USA.
Equine Vet J. 2010 Oct;42(7):643-51. doi: 10.1111/j.2042-3306.2010.00123.x.
Biomarkers have shown some in vivo promise for the detection of musculoskeletal injuries, but further study to assess biomarker levels in clinical orthopaedic disease is required.
To assess 7 serum biomarkers for the detection of musculoskeletal injuries.
Two- and 3-year-old racehorses were entered into the study (n = 238). Exit criteria were lack of training for >30 days, or completion of 10 study months. Data from horses with solitary musculoskeletal injuries and completion of >2 months were analysed. Musculoskeletal injury was considered intra-articular fragmentation (IAF), tendon or ligamentous injury (TL), stress fractures (SF) and dorsal metacarpal disease (DMD). Monthly lameness examination and serum collection were performed. Serum was analysed for glycosaminoglycan (GAG), type I and II collagen degradation (C1, 2C), type II collagen synthesis (CPII), type II collagen degradation (Col CEQ), aggrecan synthesis (CS846), osteocalcin (OC) as a marker of bone formation and (C-terminal telopeptide of type I collagen) CTX as a marker of bone degradation.
Of the 238 horses 59 injured and 71 uninjured control horses met the analysis criteria. Based on injury no significant differences in the proportions were observed for age, gender or lesion type, although a higher proportion of injuries occurred at the beginning of the study. Of injured horses, 16 (27%) sustained an IAF, 17 (29%) a TL injury, 7 (12%) SF and 19 (32%) were diagnosed with DMD. There were significant changes seen in biomarkers based on the injury incurred when longitudinal samples were assessed. Furthermore, based on the serum biomarkers collected prior to injury, horses could be correctly classified as injured or uninjured 73.8% of the time.
A unique biomarker pattern occurred before each injury and this was beneficial in classifying horses as injured or uninjured.
Biomarkers have the potential to be used as a screening aid prior to musculoskeletal injury.
生物标志物在检测肌肉骨骼损伤方面显示出一定的体内应用前景，但需要进一步研究以评估临床骨科疾病中的生物标志物水平。
评估 7 种血清生物标志物在肌肉骨骼损伤检测中的应用。
将 2 至 3 岁的赛马纳入研究（n=238）。退出标准为超过 30 天未训练或完成 10 个研究月。分析了有孤立性肌肉骨骼损伤且完成时间超过 2 个月的马匹的数据。肌肉骨骼损伤被认为是关节内碎片（IAF）、肌腱或韧带损伤（TL）、应力性骨折（SF）和背侧掌骨疾病（DMD）。每月进行跛行检查和血清采集。分析血清中糖胺聚糖（GAG）、I 型和 II 型胶原降解（C1、2C）、II 型胶原合成（CPII）、II 型胶原降解（Col CEQ）、聚集蛋白合成（CS846）、骨钙素（OC）作为骨形成的标志物和（I 型胶原 C 末端肽）CTX 作为骨降解的标志物。
在 238 匹马中，59 匹受伤马和 71 匹未受伤的对照马符合分析标准。基于损伤，在年龄、性别或病变类型方面未观察到比例有显著差异，尽管研究开始时受伤的比例较高。在受伤的马中，16 匹（27%）发生 IAF，17 匹（29%）发生 TL 损伤，7 匹（12%）发生 SF，19 匹（32%）被诊断为 DMD。对纵向样本进行评估时，发现生物标志物有显著变化。此外，根据受伤前采集的血清生物标志物，73.8%的时间可以正确地将马分类为受伤或未受伤。
每种损伤前都出现了独特的生物标志物模式，这有助于将马分类为受伤或未受伤。
生物标志物有可能在肌肉骨骼损伤前用作筛查辅助手段。
